Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.1429.

Several equities analysts have issued reports on the company. JMP Securities set a $8.00 target price on Sana Biotechnology in a research report on Thursday, October 30th. HC Wainwright dropped their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Monday, December 29th. Citizens Jmp raised their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a report on Thursday, October 30th. Finally, Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its position in Sana Biotechnology by 4.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after acquiring an additional 2,023 shares during the last quarter. Creative Planning lifted its stake in shares of Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after purchasing an additional 2,719 shares during the period. Savant Capital LLC lifted its stake in shares of Sana Biotechnology by 5.6% during the 3rd quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock worth $236,000 after purchasing an additional 3,500 shares during the period. Viewpoint Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 19.1% during the second quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock worth $77,000 after purchasing an additional 4,500 shares during the last quarter. Finally, Captrust Financial Advisors grew its position in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after purchasing an additional 4,807 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of SANA opened at $4.58 on Thursday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -4.72 and a beta of 1.96. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $6.55. The company’s fifty day moving average is $4.27 and its two-hundred day moving average is $4.04.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.03. Sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.